Although the evidence to support routine HER2 testing in NSCLC is limited, the United States National Comprehensive Cancer Network (NCCN) 2025 guidelines recommend testing for rare oncogenic driver alterations (including HER2 mutations) for better therapeutic decision-making. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.